Targeted Inhibition of Telomerase in Human Cancer: Will It Be a Double-Edged Sword?

Publisher： Karger

E-ISSN： 2296-5262|24|1|22-26

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.24, Iss.1, 2001-03, pp. : 22-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aging and Cancer: The Double‐Edged Sword of Replicative Senescence

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 45, Iss. 4, 1997-04 ,pp. : 482-488

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hypothermia: A Double-Edged Sword

By  

Cardiology, Vol. 122, Iss. 2, 2012-07 ,pp. : 126-128

Karger

Access to resources Recommend Favorite

JNK: A double‐edged sword in tumorigenesis

By  

HEPATOLOGY, Vol. 54, Iss. 4, 2011-10 ,pp. : 1470-1472

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inflammatory angiogenesis in atherogenesis—a double-edged sword

By Ribatti Domenico   Levi-Schaffer Francesca   Kovanen Petri  

Annals of Medicine, Vol. 40, Iss. 8, 2008-12 ,pp. : 606-621

Informa Healthcare

Access to resources Recommend Favorite

Erlotinib might be a double‐edged sword in HCC

By  

HEPATOLOGY, Vol. 61, Iss. 2, 2015-02 ,pp. : 729-729

John Wiley & Sons Inc

Access to resources Recommend Favorite